Clinical Trial

Second STOP After Pioglitazone Priming in CML Patients

Study acronym: PIO2STOP
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
Single-center study, prospective, phase II trial. The study objectives are : * To assess safety and pharmacokinetics of the combination of PIO and TKI in CML subjects who experience a loss of MMR following a first TKI discontinuation. * To assess survival without loss of MMR over a 12 months period following a second TKI discontinuation in subjects who achieve or maintain \< MR4.5 with the combination PIO and TKI administered for at least 6 months.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2016-08-30; most recent amendment 2026-07-01.
Status change: Not Yet Recruiting → Recruiting 2018-03-20
Trial Details
NCT Number NCT02889003
Lead Sponsor Versailles Hospital
Conditions Chronic Myeloid Leukemia (CML)
Enrollment 26 participants
Start Date 2016-12
Primary Completion 2027-12 (estimated)
Study Completion 2028-12 (estimated)
Updated on ClinicalTrials.gov 2026-07-06